Emerin

Emerin
Name	Emerin
Uniprot	P50402
Organism	Homo sapiens
Gene	EMD
Location	Inner nuclear membrane
Function	Nuclear envelope structural component

Emerin is a conserved inner nuclear membrane protein encoded by the EMD gene. First characterized in investigations of X-linked muscular dystrophy, emerin links the nuclear lamina to nucleoskeletal and chromatin-associated complexes and participates in mechanotransduction, gene regulation, and nuclear architecture. Studies across human genetics, cell biology, and model organisms including Mus musculus, Danio rerio, and Saccharomyces cerevisiae have elucidated emerin’s roles and disease associations with distinct clinical and molecular phenotypes.

Structure and biochemical properties

Emerin is a 34 kDa type II membrane protein with a short N-terminal nucleoplasmic domain, a single transmembrane helix, and a luminal C-terminal tail facing the perinuclear space; related topology is shared with other inner nuclear membrane proteins such as Lamina-associated polypeptide 2 and MAN1. The nucleoplasmic region contains an evolutionarily conserved LEM (LAP2–Emerin–MAN1) domain that mediates binding to the chromatin-bridging protein Barrier-to-autointegration factor (BAF) and to chromatin-associated factors including components of the SWI/SNF complex and transcriptional regulators like GATA4 and SRF. Emerin undergoes post-translational modifications including phosphorylation at multiple serine and tyrosine residues by kinases such as Casein kinase II and Src family kinases, O-GlcNAcylation by O-GlcNAc transferase, and sumoylation, which modulate interactions with partners like actin and lamin A/C. Biochemical fractionation and crosslinking studies identified oligomerization interfaces and binding motifs for nuclear actin-related proteins and SUN1–SUN2 complexes.

Localization and trafficking

Emerin primarily localizes to the inner nuclear membrane beneath the nuclear lamina, co-distributing with Lamin A/C, Lamin B1, and proteins of the nuclear pore complex such as Nup153. Targeting to the inner nuclear membrane depends on a conserved transmembrane domain and interactions with nuclear transport machinery including import receptors like Importin-β and components of the TRC40/Get pathway that guide tail-anchored proteins. During mitosis, emerin becomes dispersed in the endoplasmic reticulum and reassociates with reforming nuclei in coordination with kinetochore and chromatin reassembly factors such as BubR1 and Aurora B kinase. Perturbation of trafficking routes by mutations or by depletion of chaperones like Hsp70 alters emerin distribution, producing cytoplasmic mislocalization observed in cellular models and patient-derived fibroblasts.

Function and interactions

Emerin acts as a multifunctional scaffold connecting the nuclear lamina to chromatin and cytoskeletal elements. Through its LEM domain it binds BAF, coupling chromatin organization to nuclear envelope stability; through distinct sequences it associates with Lamin A/C and Nesprin-1, forming the LINC complex axis with SUN proteins to transmit mechanical signals between the cytoskeleton and nucleus. Emerin interacts with transcriptional regulators including β-catenin, HDAC3, and MKL1 (also known as MRTF-A), modulating transcriptional programs implicated in myogenesis and cardiogenesis involving factors like MyoD and MEF2C. Emerin binds nuclear actin and components of the ARP2/3 pathway, influencing chromatin mobility and repair processes mediated by DNA damage response factors such as 53BP1 and BRCA1. Phosphorylation-state–dependent changes in emerin alter its affinity for partners and affect processes ranging from nuclear stiffness to mechanosensitive gene expression observed in endothelial and skeletal muscle cells subjected to shear or tensile stressors.

Clinical significance and associated disorders

Mutations in the EMD gene cause X-linked Emery–Dreifuss muscular dystrophy (EDMD), characterized by early contractures, humeroperoneal muscle weakness, and cardiac conduction defects necessitating monitoring for arrhythmias and sudden cardiac death; clinical management often involves devices like implantable cardioverter–defibrillators and pacing. EDMD overlaps phenotypically with other nuclear envelopathies caused by mutations in LMNA, SYNE1, and TMEM43, which can produce dilated cardiomyopathy, conduction disease, and skeletal myopathy. Female carriers may show variable manifestations due to skewed X-chromosome inactivation, a process studied in relation to XIST regulation. Pathogenic mechanisms include nuclear fragility, altered mechanotransduction, dysregulated transcriptional networks involving Notch signaling and Wnt signaling, and defective DNA repair contributing to progressive tissue pathology.

Genetic variants and molecular pathology

The EMD locus on chromosome Xq28 harbors nonsense, frameshift, splice-site, and missense variants leading to truncated or unstable protein products often subject to proteasomal degradation; common recurrent lesions include early stop codons and exon deletions. Loss-of-function mutations typically produce absent or severely reduced emerin detectable by immunostaining and immunoblotting in patient myoblasts and fibroblasts, whereas hypomorphic missense variants can perturb binding interfaces with BAF or lamin A/C and alter post-translational modification sites. Genotype–phenotype correlations are complex; modifier genes such as LMNA variants, polymorphisms in cytoskeletal genes, and differential expression of chaperones influence disease severity. Molecular pathology includes disrupted nuclear envelope architecture, misregulated chromatin domains marked by altered histone modifications (e.g., H3K9me3), and impaired mechanosensitive transcriptional responses.

Model systems and experimental studies

Experimental investigation employs cell-based assays, patient-derived induced pluripotent stem cells (iPSCs), and animal models: Emd-null mice replicate aspects of cardiac conduction defects and muscle weakness and have been used to test gene-replacement strategies and antisense approaches; zebrafish emerin morphants reveal developmental myopathy and cardiac phenotypes useful for chemical screens; Drosophila models of LEM-domain perturbation elucidate conserved nuclear envelope functions. Biophysical studies using atomic force microscopy, super-resolution microscopy, and cryo-electron tomography assess nuclear stiffness and membrane architecture, while proteomics and proximity-labeling techniques (BioID) map emerin interaction networks including partners such as SUN2, Nesprin-2, and HDAC3. Therapeutic exploration includes gene therapy vectors, small molecules targeting chromatin modifiers like HDAC inhibitors, and cell-based regenerative approaches trialed in preclinical models.

Category:Nuclear membrane proteins